Pipeline

SCF Partners Acquires Flowchem, Val-Tex, and Sealweld, Leading Providers of Specialized Solutions for Midstream Infrastructure Operations and Maintenance

Retrieved on: 
Monday, March 4, 2024

The PIM business manufactures highly specialized chemicals and other products for midstream infrastructure, and consists of three businesses: Flowchem, Val-Tex, and Sealweld.

Key Points: 
  • The PIM business manufactures highly specialized chemicals and other products for midstream infrastructure, and consists of three businesses: Flowchem, Val-Tex, and Sealweld.
  • Our strategic growth plan will now accelerate under a new and focused board with significant energy and infrastructure experience.
  • Aging midstream infrastructure and rising utilization further augment the need for these solutions.
  • Together with the leadership team, we look forward to creating value in the company’s next chapter of growth.”

Pembina Pipeline Corporation Reports Record Results for the Fourth Quarter 2023, Provides Business Update, and Declares Quarterly Common Share Dividend

Retrieved on: 
Thursday, February 22, 2024

Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.

Key Points: 
  • Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.
  • Results were impacted by higher incentive costs driven by Pembina's share price performance and increased shared service revenue.
  • On a per share (basic) basis, cash flow from operating activities was $1.60 per share for the fourth quarter and $4.79 per share for the full year.
  • ET) for interested investors, analysts, brokers and media representatives to discuss results for the fourth quarter of 2023.

PodcastOne Reports Revenue of $31.6M (+22% YoY) and Adjusted EBITDA* of $405K for First Nine Months Fiscal 2024

Retrieved on: 
Thursday, February 8, 2024

PodcastOne’s President and Co-Founder, Kit Gray, commented, “We are incredibly excited about what we have accomplished in FY2024, and for what we will accomplish in FY2025.

Key Points: 
  • PodcastOne’s President and Co-Founder, Kit Gray, commented, “We are incredibly excited about what we have accomplished in FY2024, and for what we will accomplish in FY2025.
  • The enthusiasm within the organization is palpable as we set our sights on another record-breaking year ahead.
  • LiveOne currently owns approximately 73% of PodcastOne and it will continue to consolidate PodcastOne’s financial results.
  • PodcastOne was ranked 10th in PODTRAC’s Podcast Industry Top Publishers Rankings for January 2024 with a U.S.

IDTechEx Reports on Hydrogen's Decade Ahead: Energizing the Future

Retrieved on: 
Monday, January 15, 2024

IDTechEx anticipates SMR, POX, and ATR to lead the blue hydrogen sector in the coming decade, with ATR potentially dominating new production capacity by 2034.

Key Points: 
  • IDTechEx anticipates SMR, POX, and ATR to lead the blue hydrogen sector in the coming decade, with ATR potentially dominating new production capacity by 2034.
  • However, IDTechEx predicts AWE and PEMEL will lead the market in the coming decade due to their established presence.
  • Major steelmaking companies view this as the future of sustainable steel, anticipating it to replace carbon-intensive blast furnace processes.
  • IDTechEx offer access to the full portfolio of energy related research through bespoke subscription services – visit www.IDTechEx.com/Energy to find out more.

IDTechEx Reports on Hydrogen's Decade Ahead: Energizing the Future

Retrieved on: 
Monday, January 15, 2024

IDTechEx anticipates SMR, POX, and ATR to lead the blue hydrogen sector in the coming decade, with ATR potentially dominating new production capacity by 2034.

Key Points: 
  • IDTechEx anticipates SMR, POX, and ATR to lead the blue hydrogen sector in the coming decade, with ATR potentially dominating new production capacity by 2034.
  • However, IDTechEx predicts AWE and PEMEL will lead the market in the coming decade due to their established presence.
  • Major steelmaking companies view this as the future of sustainable steel, anticipating it to replace carbon-intensive blast furnace processes.
  • IDTechEx offer access to the full portfolio of energy related research through bespoke subscription services – visit www.IDTechEx.com/Energy to find out more.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Retrieved on: 
Tuesday, January 9, 2024

"Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.

Key Points: 
  • "Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections," says Peter Lawætz Andersen, Senior Vice President, Infectious Diseases at the Foundation.
  • The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products.
  • The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
  • With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X.

Everett Lott joins EXP as Vice President, Federal, State and Local Affairs

Retrieved on: 
Tuesday, December 12, 2023

WASHINGTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- EXP, a global leader in engineering, architecture, design and consulting welcomes Everett Lott as Vice President of Federal, State and Local Affairs.

Key Points: 
  • WASHINGTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- EXP, a global leader in engineering, architecture, design and consulting welcomes Everett Lott as Vice President of Federal, State and Local Affairs.
  • In this newly developed role, Everett will enhance and strengthen EXP’s government relations to support the firm’s strategic growth initiatives.
  • Everett brings over 30 years of experience to EXP in budgetary and fiscal operations, human resources, labor negotiations, contracting and procurement and public and intergovernmental relations.
  • “His understanding of federal, state and local policies, combined with his successful track record of high-value programs that directly impact communities, are unparalleled.

Homology Medicines Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.

Key Points: 
  • - Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 -
    BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.
  • There was no collaboration revenue for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022.
  • Research and development expenses for the quarter ended September 30, 2023 were $17.5 million, compared to $25.9 million for the quarter ended September 30, 2022.
  • General and administrative expenses for the quarter ended September 30, 2023 were $6.8 million, compared to $7.8 million for the quarter ended September 30, 2022.

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

Retrieved on: 
Thursday, December 14, 2023

The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.

Key Points: 
  • The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.
  • “These data add significantly to our understanding of SGR-1505 and inform our clinical development strategy in hematologic malignancies.
  • Schrödinger is presenting three new proprietary discovery programs at Pipeline Day, targeting EGFRC797S, PRMT5-MTA and NLRP3.
  • Schrödinger is advancing multiple oncology programs designed to exploit the intrinsic vulnerabilities of cancer cells through synthetic lethality and inhibition of DNA-damage repair.